Profit Margin (Quarterly) Chart

Historical Profit Margin (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 -5.19%
March 31, 2026 -3.07%
December 31, 2025 -3.78%
September 30, 2025 -0.04%
June 30, 2025 -10.90%
March 31, 2025 -17.85%
December 31, 2024 -5.04%
September 30, 2024 -6.38%
June 30, 2024 -12.81%
March 31, 2024 -25.26%
December 31, 2023 -2.97%
September 30, 2023 -18.32%
June 30, 2023 -34.31%
March 31, 2023 -50.50%
December 31, 2022 -30.94%
September 30, 2022 -21.53%
June 30, 2022 -20.48%
March 31, 2022 -32.81%
December 31, 2021 -22.88%
September 30, 2021 -34.42%
June 30, 2021 -48.79%
March 31, 2021 -74.67%
December 31, 2020 -51.00%
September 30, 2020 -59.89%
June 30, 2020 -69.16%
Date Value
March 31, 2020 -88.47%
December 31, 2019 -63.89%
September 30, 2019 -99.71%
June 30, 2019 -96.45%
March 31, 2019 -107.4%
December 31, 2018 -80.07%
September 30, 2018 -73.43%
June 30, 2018 -68.23%
March 31, 2018 -81.59%
December 31, 2017 -61.69%
September 30, 2017 -102.6%
June 30, 2017 -152.6%
March 31, 2017 -220.5%
December 31, 2016 -112.9%
September 30, 2016 -137.8%
June 30, 2016 -196.4%
March 31, 2016 -221.0%
December 31, 2015 -152.8%
September 30, 2015 -194.9%
June 30, 2015 -180.9%
March 31, 2015 -123.0%
December 31, 2014 -210.5%
September 30, 2014 -103.8%
June 30, 2014 -88.23%
March 31, 2014 -2.86%

Profit Margin Definition

Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.

Read full definition.

Profit Margin (Quarterly) Range, Past 5 Years

View Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Profit Margin (Quarterly) Benchmarks

View Profit Margin (Quarterly) Benchmarks
Start Trial
DexCom, Inc. 19.04%
Abbott Laboratories 7.37%
AngioDynamics, Inc. -13.17%
Alphatec Holdings, Inc. -12.07%
AtriCure, Inc. 5.83%